Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript

And I think that’s something we still need to learn on how far into these earlier stages or less severe stages of disease, is it sensible to actually bring in a therapy like a CAR T therapy. And I think that’s something we’ll be frank, that we still need to figure out and we need to generate data in the field, to get a better understanding of sort of where the right place and how broad that position can be. The initial positioning, we believe, is very well servable with the current types of infrastructures and technologies.

Jacob Mekhael: All right. Thank you very much. Thank you. Appreciate it.

Operator: Thank you. That’s all the time we have for questions. I’d like to turn the call back over to Christian Itin for closing remarks.

Christian Itin: Well, thank you very much for joining today. Obviously, great to have an opportunity to really review, I think, all the progress we’ve been able to go through the course of last year and into this year. A lot more to come this year. We appreciate the continued support and interest, and wish you all a great upcoming period and looking forward to connecting in person again. Thank you.

Operator: Thank you for your participation. This does conclude the program. You may now disconnect. Everyone, have a great day.